Biocheetah

BioCheetah develops non-invasive, protein-based immunodiagnostics for bladder cancer. The company creates laboratory and point-of-care assay kits, including an ELISA IVD kit and a multiplex urine biomarker POCT, supported by ISO 13485:2016 certification. Through licensing partnerships and strategic collaborations, BioCheetah commercialises diagnostics for professional and clinical use, emphasising early detection and non-invasive testing with ongoing clinical validation and evaluation across hospitals.

Biocheetah is VC-Funded and has raised funding across Seed 1 and Seed rounds. It is backed by BioSyngen and Dg (Singapore) Holding Pte. Ltd..

Alternatives.pe tracks Biocheetah's funding history, valuation trends, ownership structure, and transaction activity over time.

You're on a preview of a profileGet a free trial to view it in full

Last Updated: 2026-07-21

You're on a preview of a profileGet a free trial to view it in full

Last Updated: 2026-07-21

Loading, please wait...

All information here may not be reproduced without explicit written permission from Alternatives.pe.

Glossary

Biocheetah

Biocheetah

Documents

Employee Count

Key Team Members

Documents

Employee Count

Key Team Members